28 ACP H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES D E PARTM E NT OF PHAR MACY PR AC TI CE PUBLICATIONS
Chemotherapy 2016 Apr
Pharmacy, 2016 Aug 3
Saroka RM, Kane MP,
Neely MN, Gulati A,
22;60(5):3170-3.
(ePub ahead of print).
Robinson L, Busch RS. No
Scheetz MH. Evaluation
postoperative adrenal
of Vancomycin Exposures
Monique Bidell Bidell MR, McLaughlin M,
Jo Carreno
Davis JM, Wegrzyn N,
insufficiency in a patient
Associated with Elevations
Faragon J, Morse C, Patel
Carreno JJ, Kenney RM,
Cardone KE. Sweetening
with unilateral cortisol-se-
in Novel Urinary Biomark-
N. Desirable Charac-
Divine G, Vazquez JA,
the deal: Effects of SGLT-
creting adenomas treated
ers of Acute Kidney Injury
teristics of Hepatitis C
Davis SL. Randomized
2 inhibitors in kidney
with mifepristone before
in Vancomycin-Treated
Treatment Regimens: A
Controlled Trial to Deter-
disease progression. iFo-
surgery. Clinical Med In-
Rats. Antimicrobial Agents
Review of What We Have
mine the Efficacy of Early
rumRx, November 2016.
sights: Endocrinology and
and Chemotherapy, 2016
and What We Need.
Switch From Vancomycin
Diabetes, 2016;9:31-6.
Sep 23;60(10):5742-51.
Infectious Diseases and
to Vancomycin Alterna-
Jacqueline Cleary
Therapy 2016 Jul 6 (ePub
tives as a Strategy to
Cleary J, Nicewicz K, Fu-
Kane MP, Hamilton RA.
Lodise TP, Bidell MR, Fla-
ahead of print).
Prevent Nephrotoxicity in
din J. Life-Saving Nalox-
Determination of the gly-
nagan SD, Zasowski EJ,
Patients With Multiple Risk
one: Review of Currently
cemic index of a diabetes
Minassian SL, Prokocimer
Lodise TP, Bidell MR,
Factors for Adverse Renal
Approved Products. Prac-
truffle. Journal of Global
P. Characterization of the
Flanagan SD, Zasowski
Outcomes (STOP-NT). An-
tical Pain Management,
Diabetes and Clinical Me-
haematological profile
EJ, Minassian SL, Proko-
nals of Pharmacotherapy,
2016 September 16(7).
tabolism, 2016;1:22-4.
of 21 days of tedizolid
cimer P. Characterization
2016 Nov 11. Atkinson TJ, Pratt Cleary
Brady SM, Kane MP,
Journal of Antimicrobial
of the haematological
in healthy subjects.
profile of 21 days of
Carreno JJ, Lomaestro
J, Fudin J. 10 Pain Medi-
Busch RS. GLP-1 Agonist
Chemotherapy, 2016
tedizolid in healthy
B, Jacobs AM, Meyers
cation Myths: Challenges
Use in a Patient with
Sep;71(9):2553-8.
subjects. Journal of Anti-
RM, Evans A, Montero
in Selecting the Appropri-
an Explainable Cause
microbial Chemotherapy
C. Assessment of Time
ate Analgesic. Practical
of Pancreatitis. AACE
Jensen IS, Wu E, Fan W,
2016 Jun 17 (ePub ahead
to Clinical Response
Pain Management, 2016
Clinical Case Reports.
Lodise TP, Nicolau DP,
of print).
in Patients with Sepsis
July/August 16(6): 63-70.
Spring, 2016. DOI 10.4158/
Dufour S, Cyr PL, Sulham
EP15658.CR.
KA. Use of Oritavancin
Treated Before and After
in Moderate-to-Severe
Bidell MR, Lodise TP.
a Implementation of a
Michael Kane
Fluoroquinolone-Associ-
Matrix-Assisted Laser De-
Stryker MD, Kane MP,
Thomas Lodise
ABSSSI Patients Requiring
ated Tendinopathy: Does
sorption Ionization Time
Busch RS. Lack of
Rahbar AJ, Lodise TP,
IV Antibiotics: A U.S. Pay-
Levofloxacin Pose the
of Flight Based Blood
Cross-Reactivity Allergy
Abraham P, Lockwood
er Budget Impact Analy-
Greatest Risk? Pharmaco-
Culture Identification Al-
Following a Switch from
A, Pai MP, Patka J, Rabi-
sis. Journal of Managed
therapy 2016 May 3
gorithm. Infection Control
Alirocumab to Evolocum-
novich M, Curzio K, Ches-
Care & Specialty Pharma-
(ePub ahead of print).
& Hospital Epidemiology,
ab. Excerpts in Pharma-
ter K, Williams B, Morse B,
cy, 2016 Jun;22(6):752-
2016 Aug;37(8):916-23.
cy Research Journal,
Chaar M, Huang V, Salo-
64. doi: 10.18553/
doi: 10.1017/ice.2016.105.
2016;2:1-3.
mone J. Pharmacokinetic
jmcp.2016.22.6.752.
Bidell MR, Palchak M,
and Pharmacodynamic
Mohr J, Lodise TP. Fluoroquinolone and Third-Gen-
Katie Cardone
Stryker MD, Kane MP,
Evaluation of Doripenem
Bidell MR, Palchak M,
eration Cephalosporin
Parker WM, Ferreira K,
Busch RS. An Evaluation
in Critically Ill Trauma
Mohr J, Lodise TP. Fluoro-
Resistance among
Vernon L, Cardone KE.
Of Proprotein Convertase
Patients with Sepsis. Sur-
quinolone and Third-Gen-
Hospitalized Patients with
The delicate balance of
Subtilisin/Kexin Type
gical Infections (Larchmt),
eration-Cephalosporin
Urinary Tract Infections
keeping it all together:
9 (PCSK9) Inhibitors In
2016 Dec;17(6):675-682.
Resistance among
Due to Escherichia
Using social capital
Patients With Diabetes
coli: Do Rates Vary by
to manage multiple
Mellitus. Journal of Clini-
Rhodes NJ, Prozialeck
Urinary Tract Infections
Hospital Characteristics
medications for patients
cal Lipidology, 10(3):720,
WC, Lodise TP, Venka-
Due to Escherichia coli:
and Geographic Region?
on dialysis. Research in
May 2016.
tesan N, O’Donnell JN,
Do Rates Vary by Hospi-
Antimicrobial Agents and
Social and Administrative
Pais G, Cluff C, Lamar PC,
tal Characteristics and
Hospitalized Patients with